Heidelberg Epignostix GmbH

🎄As this year comes to a close, we are filled with gratitude for the exciting year we have had thanks to all our partners, collaborators and the community! The Heidelberg Epignostix team wishes you warmth, joy, and success in the coming year. Here's to an incredible 2025!🥂 ✨Happy holidays and a wonderful New Year!✨

Very well deserved recognition for our co-founder! Congratulations, David 🥳

🚀 Heidelberg Epignostix GmbH Secures €4.3M to Revolutionize Cancer Diagnostics! Heidelberg Epignostix GmbH has raised €4.3 million in seed funding to fast-track the development of its cutting-edge cancer diagnostics technology.🎉 Supported by CARMA FUND Management GmbH, HTGF | High-Tech Gründerfonds, @LBBW Venture Capital GmbH, and the Start-up BW Seed Fund, the investment will drive market expansion for the company's brain tumor classification platform, which utilizes DNA methylation and AI-powered bioinformatics to enable more precise cancer diagnostics. The technology is based on over 10 years of research at Heidelberg University, DKFZ German Cancer Research Center, UKHD and the Hopp Children's Cancer Center Heidelberg (KiTZ)), and has already been applied to more than 150,000 patient samples. Initial efforts are focused on brain tumors, particularly in childhood cancer, where diagnostic accuracy is critical. 🔬 What’s next? The Heidelberg Brain Classifier is expected to launch as a World Health Organization-recommended diagnostic test by 2025, with plans to extend its use to other tumor types shortly thereafter. #CancerDiagnostics #Epigenetics #AI #Bioinformatics #HealthcareInnovation #Startups #Biotech #Heidelberg #DKFZ

🚀 Heidelberg Epignostix GmbH Secures €4.3M to Revolutionize Cancer Diagnostics! 🌟 Exciting news from Heidelberg Epignostix GmbH as the company has successfully raised €4.3 million in seed funding to accelerate the development of its innovative cancer diagnostics technology! 💸 Supported by CARMA FUND Management GmbH, HTGF | High-Tech Gründerfonds, LBBW Venture Capital GmbH, and the Start-up BW Seed Fund, this investment will help expand the market for their brain tumor classification platform. 🧬 The platform leverages DNA methylation and AI-powered bioinformatics to provide more accurate cancer diagnoses. 💡 With over 10 years of research from Heidelberg University, DKFZ German Cancer Research Center, University Hospital Heidelberg (UKHD), and the Hopp Children's Cancer Center Heidelberg (KiTZ), this cutting-edge technology has already been applied to over 150,000 patient samples. Initial efforts are focused on brain tumors in children, where diagnostic precision is crucial. 💥 Groundbreaking news - The Heidelberg Brain Classifier is on track to become a WHO-recommended diagnostic test by 2025, with plans to expand to other tumor types soon after! 🎉 Congratulations to Heidelberg Epignostix GmbH and their team! #CancerDiagnostics #Epigenetics #AI #Bioinformatics #HealthcareInnovation #Startups #Biotech #Heidelberg #DKFZ

🌟 Reflecting on the Summit "Innovation and Equity in Health Tech" 🌟 The DKFZ Innovation Management team is thrilled to share highlights from this inspiring event, which brought together founders, investors, young scientists, and innovation professionals to exchange insights, foster collaboration, and strengthen our entrepreneurial community. 🎤 Highlights: 1️⃣ Prof. Dr. Eckart Würzner, Mayor of Heidelberg, reaffirmed the city's commitment to startups and entrepreneurship, following his recent awarding of the Heidelberg Gründerpreis. 2️⃣ Ursula Weyrich unveiled DKFZ’s innovation strategy, underscoring the importance of entrepreneurship in advancing cancer research and naming the participating DKFZ spin-offs, Panosome GmbH, Merall Bioproducts and Heidelberg Epignostix GmbH. 3️⃣ Ina Schlie tackled the challenges of investing in German and European spin-offs, proposing actionable solutions to close the gap with the US. 4️⃣ Prof. Dr. Heike Marita Hölzner emphasized the value of eye-level relationships between founders and investors for long-term success during her insights on archetypes of business angels. 5️⃣ Founders Panel: Helge Lubenow shared that it’s crucial to know what you own and what makes it unique. 6️⃣ Nina Papavasiliou, Rainer Wessel and Martina Pfeifer shared what competences it takes to start a company. Martina highlighted her focus on founding teams and rigorous due diligence in early-stage investments. 7️⃣ Investor Panel: Key advice included Andreas Schmidt’s insight: “Ask for advice if you want money,” and Heino Freudenberg’s encouragement to embrace failure as a growth opportunity. 8️⃣ Birgit Zech, Anavo Therapeutics BV, inspired the audience with her international perspective, shedding light on cultural differences in startup ecosystems. ✨ Other Moments: • Julia Yukovich's trends into what AI has to offer in Health Tech. • Engaging startup pitches by TimeTeller GmbH, Noxon GmbH, myScribe GmbH, Meddenovo Drug Design, Dermagnostix; Xena Dx (Techstars '23) 💡 Key Takeaway: "Close and early interaction between business angel networks, founders, and transfer offices is vital for successful spin-offs from public research centers." – Rainer Wessel Young scientists brought fresh energy to the discussions, many sharing how the summit inspired them to think strategically about their potential in health tech. A heartfelt thank you to all participants, volunteers, and partners — encourageventures e.V., Heidelberg Startup Partners e.V., Health + Life Science Alliance and H3 Health Hub — for making this event a true success. #InnovationAndEquity #HealthTech #Entrepreneurship #Startups #DKFZ #Heidelberg #Gründungswoche Deutschland 2024

We’re glad to have you onboard, Sruthi! 🚀Welcome to the team!

Wieder viel Interessantes im neuen transkript! Nicht nur die Kurzprofile von aitiologic, Heidelberg Epignostix GmbH, NatIgGs GmbH und PRAMOMOLECULAR , sondern auch ein Interview mit Werner Lanthaler nach seinem Rücktritt als CEO von Evotec, die KI-Strategie von BioNTech SE und viele weitere kurze bis ausführliche Informationen aus den Life Sciences der DACH-Region! https://lnkd.in/eBSm-_nq

𝟑𝟎 𝐝𝐚𝐲𝐬 𝐭𝐨 𝐠𝐨!  This year´s 𝗕𝗶𝗼𝗥𝗡 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 program is dedicated to show all the excellent science around the topic "𝗡𝗲𝘄 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗠𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝗶𝗻 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘀𝗲𝗱 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲", 🚀 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟵𝘁𝗵 is the day, 🎯 Heidelberg Congress Center is the perfect location Looking forward to the presentations on groundbreaking technological advancements, that #radiopharmaceuticals and #antibody drug conjugates opened up remarkable capabilities towards clinical development. Let´s learn how #epigenetics, #RNA biology, and molecular #precision diagnostics will uncover the avenues for other novel therapeutic modalities holding great promise for individual treatments.  The #BioRNConference will bring together expertise in basic, applied and clinical research in these fields, fostering new perspectives and visions for personalised medicine. At transkript online you can find more information about the speakers: https://lnkd.in/eeQEWEve (German language) What are you waiting for? 𝐅𝐢𝐧𝐝 𝐭𝐡𝐞 𝐚𝐠𝐞𝐧𝐝𝐚 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐥𝐢𝐬𝐭 𝐡𝐞𝐫𝐞: ▶https://lnkd.in/dQvysUw ▶ and register now: https://bit.ly/49lgGcP Tap into one of the most vibrant Life Science Ecosystems in Europe! See you there! Heidelberg Pharma AG; DKFZ Deutsches Krebsforschungszentrum; Heidelberg Epignostix GmbH; VERAXA Biotech GmbH; Stoecklin Georg; NEC Bio Therapeutics GmbH; BioM Biotech Cluster Development GmbH; BioPharma Cluster South Germany; Oslo Cancer Cluster;

I feel very honored being able to join such a world-class team and am deeply impressed about the achievements that have been made already. I am committed to improving cancer care and quality of life outcomes for the benefit of patients and their families, community and ultimately society!

We are thrilled to announce the appointment of Helge Lubenow as our new CEO! 🚨 A very warm welcome from the entire team! Read more here: https://lnkd.in/eNXu_ADU David Jones, Felix Sahm, Martin Sill, Natalie Jäger, Daniel Schrimpf, Areeba Patel, Prof. Dr. med. Stefan M. Pfister, Andreas von Deimling, David Capper, Matija Snuderl, Martin Raditsch, PhD, RTTP, Katharina Severin, Caroline Lehmann, Josef Walek, Rainer Wessel